Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Your health history is reviewed before starting
Collectively, these findings identified EV-derived VDAC1 transfer as a novel therapeutic target for overcoming PTX resistance in GC, highlighting the dual role in modulating both mitochondrial homeostasis and autophagic flux
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
Last reviewed: June 6, 2026 Last updated: June 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
:max_bytes(150000):strip_icc():focal(749x311:751x313)/Gabriel-IglesiasMayim-Bialik-and-Valerie-Bertinelli-060926-5ce5ab701dc546efb795b828cec51c2c.jpg)
